ESC Premium Access

The effect of monoclonal antibodies against PCSK9 on circulating CD34+ progenitor cells interactions with platelets in patients with familial hypercholesterolemia.

Congress Session

About the speaker

Mrs Aikaterini Tsouka

University of Ioannina, Ioannina (Greece)
0 follower

4 more presentations in this session

State of the Art - PCSK9 in inhibitors therapy in clinical therapy

Speaker: Professor S. Nicholls (Melbourne, AU)

Thumbnail

The effect of proprotein convertase subtilisin kexin type 9 (PCSK9) inhibitors on endothelial progenitor cells

Speaker: Doctor O. Itzhaki Ben Zadok (Petah Tikva, IL)

Thumbnail

Treatment of Hypercholesterolaemia with PCSK9 Inhibitors in Denmark. Assessment of real-life data; Extent and Efficacy after the first years of clinical use

Speaker: Doctor S. Mulverstedt (Copenhagen, DK)

Thumbnail

Positioning PCSK9 inhibitors therapy in clinical practice.

Speaker: Professor K. Ray (London, GB)

Thumbnail

Access the full session

PCSK9 inhibitors: from cells to patients

Speakers: Mrs A. Tsouka, Professor S. Nicholls, Doctor O. Itzhaki Ben Zadok, Doctor S. Mulverstedt, Professor K. Ray
Thumbnail

About the event

Image

ESC CONGRESS 2019

31 August - 4 September 2019

Sessions Presentations

This platform is supported by

logo Novo Nordisk